With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Stapled Peptide PROTAC: A 3-in-1 Treatment for Pediatric Solid Tumors||Dana-Farber Cancer Institute / Loren Walensky, MD/PhD||Reach Grants||2021||Massachusetts|
|Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG||Mayo Clinic / David Daniels, MD/PhD||Reach Grants||2021||Minnesota|
|IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas||Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD||Reach Grants||2021||New York|
|The Interplay Between Histone Mutations and Replication Stress in Shaping Glioma Phenotypes||Dana-Farber Cancer Institute / Pratiti Bandopadhayay, PhD||'A' Award Grants||2021||Massachusetts|
|Circulating Tumor Biomarkers: New Paradigms for Management of Neuroblastoma||University of Chicago / Mark Applebaum, PhD||'A' Award Grants||2021||Illinois|
|GD2-directed CAR T cell therapy for H3K27M+ spinal cord diffuse midline glioma||Board of Trustees of the Leland Stanford Junior University / Michelle Monje||Catalyst Grants||2021||California|
|Turning Killers into THINKers: TME Hostility-Impervious NK Cells for Treating Neuroblastoma and Sarcoma||Baylor College of Medicine / Robin Parihar, MD/PhD||'A' Award Grants||2021||Texas|
|Role of PHF6 Mutations in Germline RUNX1 Deficiency Associated Hematopoietic Disorders||Boston Children's Hospital / Serine Avagyan, MD/PhD||RUNX1 Early Career Investigator Grants||2021||Massachusetts|
|Targeting CCAAT/enhancer binding proteins CEBPB and CEBPD in neuroblastoma||Columbia University / Darrell Yamashiro, MD/PhD||Innovation Grants||2021||New York|
|In-vivo characterization of MYCN-driven immunosuppression||University of California San Francisco / William Weiss, MD/PhD||Innovation Grants||2021||California|